|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 05, 2018 ) The global antinuclear antibody (ANA) test market is expected to reach USD 1,476.1 Million by 2021 from USD 823.5 Million in 2016, at a CAGR of 12.4%. In this report, the ANA testing market is broadly classified based on products, diseases, techniques, end users, and regions.
Browse 73 market data Tables and 102 Figures spread through 166 Pages and in-depth TOC on "Antinuclear Antibody Test Market".
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=218189007
Based on products, the antinuclear antibody test market is segmented into assay kits & reagents, systems, and software & services. The assay kits & reagents segment is expected to account for the largest share of the global ANA testing market in 2016. The growth in this segment can majorly be attributed to the growth in the number of reagent rental agreements and increasing prevalence of autoimmune diseases.
The antinuclear antibody test market is segmented into five major disease segments, namely, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, scleroderma, and other diseases. Other diseases include Raynaud’s Syndrome, polymyositis, mixed connective tissue disease, drug-induced lupus, and autoimmune hepatitis. The rheumatoid arthritis segment is expected to account for the largest market share, primarily due to the increasing incidence of rheumatoid arthritis.
Based on techniques, the antinuclear antibody test market is segmented into enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), and multiplex assay. The ELISA segment is expected to account for the largest share of this market due to the expanding applications of ANA in autoimmune disease testing and therapeutic drug level monitoring.
The end user segments in the antinuclear antibody test market include clinical laboratories, hospitals, POLs, and other end users. The hospitals segment is expected to account for the largest share of the global ANA testing market in 2016. Growth in this segment can be attributed to the fact that most diagnostic tests are performed in hospitals or hospital-attached laboratories, primarily due to easy access to reports and smooth logistics.
Know More: https://www.marketsandmarkets.com/PressReleases/antinuclear-antibody-test.asp
North America is the largest regional segment in the ANA testing market, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American market is primarily driven by the high incidence of autoimmune diseases, growing population and healthcare spending, and growth in the number of individuals covered under medical insurance in the U.S.
The major players in the antinuclear antibody test market are Alere Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.), EUROIMMUN AG (Germany), Immuno Concepts (U.S.), Inova Diagnostics (U.S.), and Zeus Scientific, Inc. (U.S.).
MarketsandMarkets
Mr. Shelly Singh
1-888-600-6441
sales@marketsandmarkets.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
